Trial of Ibrutinib Plus Trastuzumab in HER2-amplified Metastatic Breast Cancer
A phase 1/2 trial of Trastuzumab and Ibrutinib in advanced solid tumours, run by US Oncology Research, active and no longer recruiting.
Overview
Trial of Ibrutinib Plus Trastuzumab in HER2-amplified Metastatic Breast Cancer is a phase 1/2 interventional study registered as NCT03379428 by US Oncology Research, with 34 participants enrolled, started 2017-11-29 and due to reach its primary completion in 2025-01. Interventions recorded: Trastuzumab, Ibrutinib 560 mg, Ibrutinib 840 mg and Ibrutinib 420 mg.
Similar pages
not linked directly; found by shared links- TrialPhII ICb With/Without Erbitux in MBC Pts
Shares McKesson / The US Oncology Network, Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialA Study to Customize Ibrutinib Treatment Regimens for Participants With Previously Untreated Chronic Lymphocytic Leukemia
Shares Ibrutinib, AbbVie (incl. ImmunoGen, Capstan) and the tag pipeline.
- TrialA Study to Assess Adverse Events and Change in Disease Activity in Participants 12 Years of Age or Older With Locally Advanced or Metastatic Solid Tumors That Harbor MET Amplification Receiving Intravenously Infused Telisotuzumab Adizutecan
Shares AbbVie (incl. ImmunoGen, Capstan), Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialA Safety and Efficacy Extension Study of Pertuzumab in Patients With Solid Tumors Previously Enrolled in a Hoffmann-La Roche-Sponsored Pertuzumab Clinical Trial
Shares Trastuzumab, Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialTucatinib+Trastuzumab+Eribulin in HER2+ MBC
Shares Trastuzumab, Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialA Trial of Trastuzumab Rezetecan in Unresectable Locally Recurrent/Metastatic Breast Cancer
Shares Trastuzumab, Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialA Study of Tucatinib (MK-7119) in Combination With Trastuzumab and Capecitabine in Participants With Previously Treated Locally Advanced Unresectable or Metastatic Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Breast Carcinoma (MK-7119-001)
Shares Trastuzumab, Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialRollover Study to Provide Continued Treatment for Participants With B-Cell Malignancies Previously Enrolled in Studies of Parsaclisib (INCB050465)
Shares Ibrutinib, Metastatic cancer (cancer that has spread) and the tag pipeline.